CompletedPhase 1NCT02601937
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Studying Synovial sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Epizyme, Inc.
- Principal Investigator
- Ipsen MedicalIpsen
- Intervention
- Tazemetostat(drug)
- Enrollment
- 109 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2016 – 2021
Study locations (30)
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- University of California San Francisco - Benioff Children's Hospital, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- John Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Massachusetts General Hospital - Cancer Center, Boston, Massachusetts, United States
- Memorial Sloan Kettering, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Oregon Health & Science University (OHSU), Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Inc., Memphis, Tennessee, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02601937 on ClinicalTrials.govOther trials for Synovial sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07174427Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial SarcomaTakara Bio Inc.
- RECRUITINGPHASE1NCT06946225ACTengine® IMA203 Combined With mRNA-4203Immatics US, Inc.
- RECRUITINGNCT05910307Synovial Sarcoma Registry / Biospecimen RepositoryChildren's Hospital of Philadelphia